Nifedipine Use Patterns in Preeclamptic Pregnant Women at Dr. Mohammad Hoesin Hospital

Abstract

Preeclampsia is a condition in pregnant women characterized by hypertension, defined as a systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, along with proteinuria ≥ 300 mg. Nifedipine, a calcium channel blocker, is commonly used in the treatment of preeclampsia due to its rapid onset of action and lack of teratogenic effects. This study aims to determine the pattern of nifedipine use in pregnant women with preeclampsia at Mohammad Hoesin Hospital, Palembang. This drug utilization study was conducted using medical records of pregnant women diagnosed with preeclampsia at Mohammad Hoesin Hospital from June 1, 2020, to July 31, 2022. A total of 210 samples were obtained using total sampling. Data were collected based on inclusion criteria and analyzed using SPSS version 24.0 for Windows. Among the 210 patients with preeclampsia, the majority were diagnosed with severe preeclampsia (99%), aged over 35 years (54.3%), housewives (85.2%), multigravida (68.6%), multiparous (40.5%), and in the third trimester of pregnancy (95.2%). Nifedipine was administered at a dose of 10–20 mg (100%), with a frequency of ≤ 4 times per day (100%), and a duration of ≥ 1 day (100%). Most drug interactions observed were of the synergistic type (21%). One patient (0.5%) had a contraindication (mitral regurgitation) and did not meet the inclusion criteria. The pattern of nifedipine use in pregnant women with preeclampsia at Mohammad Hoesin Hospital was appropriate based on rational drug use criteria, including correct dosage (100%), frequency of administration (100%), duration of treatment (100%), and drug interaction profile (100%).